Skip to main content
ACAD
NASDAQ Life Sciences

Remlifanserin Phase 3 Misses Primary Endpoint, Acadia Shares Plunge 12%

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$23.95
Mkt Cap
$4.382B
52W Low
$19.69
52W High
$30.96
52W Position info
22% above low
Off High info
23% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ACAD sits 22% above its 52-week low of $19.69.

Summary

Acadia's Phase 3 topline results for remlifanserin in Alzheimer's disease psychosis missed the primary endpoint, with the 60 mg dose showing a -12.6 change vs -10.4 for placebo (p=0.0603). The 30 mg dose showed minimal improvement. The stock dropped 12% premarket to $22.50. The company plans to continue enrolling two ongoing Phase 3 studies with amendments, including removing the 30 mg arm. This is a major setback for a key pipeline asset, especially after the FDA granted Fast Track designation in July. The miss raises doubts about the drug's efficacy in a large market with no approved therapies.

At the time of this announcement, ACAD was trading at $23.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $19.69 to $30.96. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

ACAD - Latest Insights

ACAD
Nov 04, 2026, 6:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.95
Real-time Price: $21.20 info
Change: -$0.7512 (-3%) info
Market Cap: $3.66B info
ACAD
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.46
Real-time Price: $21.20 info
Change: -$0.260 (-1%) info
Market Cap: $3.66B info
ACAD
Oct 05, 2026, 2:23 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $20.07
Real-time Price: $21.20 info
Change: +$1.13 (+6%) info
Market Cap: $3.66B info
ACAD
Sep 28, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.53
Real-time Price: $21.20 info
Change: +$0.670 (+3%) info
Market Cap: $3.66B info
ACAD
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.65
Real-time Price: $21.20 info
Change: +$0.550 (+3%) info
Market Cap: $3.66B info